Please login to the form below
Sutimlimab
This page shows the latest Sutimlimab news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
Sutimlimab – a first-in-class selective inhibitor of complement C1s – has hit the mark in cold agglutinin disease (CAD), a rare, autoimmune form of haemolytic anaemia that causes blood clots, leading ... In the phase 3 CARDINAL study reported at the
Latest news
-
Sanofi exits R&D pact with Alnylam on rare disease
The French drugmaker is also working on sutimlimab, an antibody for cold agglutinin disease in phase 3 testing, long-acting clotting factor BIVV001 for haemophilia A (phase 2) and gene-editing
Sanofi exits R&D pact with Alnylam on rare disease
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
